Latest Ratios: P/E Ratio 21.5x · EV/EBITDA 16.4x · ROE 19.7%. (1998–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $24.8B | $23.3B | $17.1B | $10.9B | $13.5B | $10.2B | $6.8B | $3.9B | $4.8B | $6.6B | $6.7B |
| Enterprise Value | $23.3B | $21.8B | $15.7B | $10.4B | $13.3B | $10.1B | $6.8B | $4.0B | $4.4B | $6.2B | $5.7B |
| P/E Ratio → | 21.50 | 17.49 | 14.32 | 11.10 | 18.54 | 21.48 | 13.15 | — | 8.13 | 15.89 | 9.41 |
| P/S Ratio | 7.78 | 7.33 | 5.95 | 4.70 | 6.97 | 6.06 | 4.56 | 2.66 | 2.94 | 3.85 | 4.20 |
| P/B Ratio | 3.94 | 3.29 | 2.66 | 1.83 | 2.81 | 2.58 | 1.99 | 1.39 | 1.72 | 3.16 | 3.60 |
| P/FCF | 28.59 | 22.43 | 15.84 | 14.62 | 20.32 | 21.41 | 9.72 | — | 8.07 | 17.13 | 11.18 |
| P/OCF | 15.88 | 14.95 | 12.89 | 11.17 | 16.81 | 17.09 | 8.96 | — | 6.16 | 14.01 | 10.43 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.86 | 5.46 | 4.48 | 6.88 | 6.01 | 4.61 | 2.74 | 2.69 | 3.59 | 3.56 |
| EV / EBITDA | 16.41 | 13.61 | 10.84 | 8.42 | 12.93 | 16.71 | 10.62 | — | 5.20 | 7.32 | 5.20 |
| EV / EBIT | 15.34 | 12.59 | 9.93 | 7.81 | 13.47 | 14.74 | 11.45 | — | 5.45 | 6.05 | 5.37 |
| EV / FCF | — | 20.97 | 14.54 | 13.94 | 20.08 | 21.21 | 9.81 | — | 7.36 | 15.95 | 9.48 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.9% | 87.9% | 89.2% | 88.9% | 92.4% | 92.7% | 92.7% | 91.9% | 87.8% | 93.9% | 95.5% |
| Operating Margin | 47.7% | 47.7% | 47.9% | 50.9% | 50.6% | 33.0% | 40.0% | -12.9% | 49.5% | 47.2% | 66.4% |
| Net Profit Margin | 41.9% | 41.9% | 41.5% | 42.3% | 37.6% | 28.2% | 34.7% | -7.2% | 36.2% | 24.2% | 44.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.7% | 19.7% | 19.2% | 18.3% | 16.6% | 12.9% | 16.7% | -3.8% | 24.1% | 21.1% | 41.2% |
| ROA | 17.5% | 17.5% | 16.4% | 14.9% | 13.0% | 9.7% | 12.1% | -2.9% | 18.8% | 16.1% | 31.6% |
| ROIC | 21.4% | 21.4% | 19.6% | 17.6% | 17.3% | 11.4% | 14.0% | -5.3% | 30.1% | 49.2% | 98.8% |
| ROCE | 21.8% | 21.8% | 21.2% | 19.6% | 18.5% | 12.1% | 15.3% | -5.7% | 29.0% | 36.8% | 56.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.05 | 0.12 | 0.17 | 0.20 | 0.24 | 0.31 | 0.09 | 0.12 | — |
| Debt / EBITDA | 0.02 | 0.02 | 0.21 | 0.57 | 0.78 | 1.32 | 1.24 | — | 0.30 | 0.30 | — |
| Net Debt / Equity | — | -0.21 | -0.22 | -0.08 | -0.03 | -0.02 | 0.02 | 0.04 | -0.15 | -0.22 | -0.55 |
| Net Debt / EBITDA | -0.95 | -0.95 | -0.96 | -0.41 | -0.16 | -0.16 | 0.10 | — | -0.50 | -0.54 | -0.94 |
| Debt / FCF | — | -1.46 | -1.29 | -0.68 | -0.24 | -0.20 | 0.09 | — | -0.71 | -1.17 | -1.70 |
| Interest Coverage | 88.89 | 88.89 | 36.87 | 22.49 | 30.52 | 36.93 | 25.38 | -2.73 | 57.73 | 113.60 | 271.59 |
Net cash position: cash ($1.6B) exceeds total debt ($38M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.60 | 6.60 | 5.25 | 4.41 | 9.85 | 7.61 | 6.70 | 4.03 | 6.39 | 3.26 | 4.29 |
| Quick Ratio | 6.28 | 6.28 | 5.03 | 4.28 | 9.55 | 7.30 | 6.44 | 3.83 | 6.03 | 3.01 | 3.98 |
| Cash Ratio | 2.78 | 2.78 | 4.43 | 3.72 | 8.27 | 6.32 | 5.68 | 3.21 | 5.12 | 2.09 | 3.16 |
| Asset Turnover | — | 0.40 | 0.39 | 0.32 | 0.32 | 0.33 | 0.32 | 0.37 | 0.48 | 0.60 | 0.69 |
| Inventory Turnover | 2.10 | 2.10 | 1.96 | 2.30 | 1.44 | 1.31 | 1.25 | 1.26 | 1.97 | 0.98 | 0.73 |
| Days Sales Outstanding | — | 40.16 | 35.43 | 43.74 | 41.55 | 43.03 | 38.73 | 38.14 | 39.40 | 62.85 | 48.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.7% | 5.7% | 7.0% | 9.0% | 5.4% | 4.7% | 7.6% | — | 12.3% | 6.3% | 10.6% |
| FCF Yield | 3.5% | 4.5% | 6.3% | 6.8% | 4.9% | 4.7% | 10.3% | — | 12.4% | 5.8% | 8.9% |
| Buyback Yield | 4.0% | 4.3% | 5.9% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 3.8% | 7.4% |
| Total Shareholder Yield | 4.0% | 4.3% | 5.9% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 3.8% | 7.4% |
| Shares Outstanding | — | $48M | $49M | $50M | $49M | $47M | $45M | $44M | $44M | $45M | $47M |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UTHR stock.
United Therapeutics Corporation's current P/E ratio is 21.5x. The historical average is 31.5x. This places it at the 70th percentile of its historical range.
United Therapeutics Corporation's current EV/EBITDA is 16.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.0x.
United Therapeutics Corporation's return on equity (ROE) is 19.7%. The historical average is 5.3%.
Based on historical data, United Therapeutics Corporation is trading at a P/E of 21.5x. This is at the 70th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
United Therapeutics Corporation has 87.9% gross margin and 47.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
United Therapeutics Corporation's Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Tyvaso generic and Winrevair competition
Metrics are mathematically derived from official filings.
Premium Multiples Price in Pipeline Optionality
Based on reported figures, UTHR trades at a 20.17 trailing P/E and 13.94 EV/EBITDA, a discount to the 40.48 P/E of Halozyme yet a premium to the 9.27 P/E of ACADIA, while revenue growth has slowed to roughly 4.1 percent year over year.
A trailing P/E of 20.17 paired with a forward P/E of 22.56 implies that consensus expects earnings to contract over the next period, which is inconsistent with a simple growth multiple and suggests the valuation leans on sustained margins rather than expansion. The PEG of 1.05 appears reasonable only if one accepts the pipeline contribution as durable, since reported top-line growth has decelerated sharply from mid-teens rates. Investors should monitor whether the 3.79 price-to-book multiple remains supportable as the asset base grows without commensurate earnings gains.
Margin Compression From Peak Levels
According to reported quarterly figures, UTHR's operating margin fell from roughly 48.7 percent in 2025Q3 to 37.0 percent in 2026Q3, while gross margin held near 88 percent, indicating the decline originates below the gross line.
Because gross margin has remained stable in the high-80s, the compression in operating margin likely reflects rising R&D and operating expense rather than pricing or cost-of-goods pressure in the core franchise. This pattern suggests net margin of 31.1 percent in the latest quarter may understate underlying franchise economics if pipeline spending is discretionary, though that interpretation depends on whether the spend yields future revenue. Operating margin is the more informative measure of current earning power here, since net margin is volatile with interest and other income.
Returns Eroding Despite Strong Franchise
As reported in financial statements, UTHR's ROIC declined to 4.8 percent in 2026Q3 from 5.7 percent in 2025Q1, while ROE of 4.1 percent sits well below the 180.6 percent reported for Halozyme, reflecting a large equity base relative to earnings.
The low ROIC and ROE appear driven by a substantial cash and equity base accumulating against modest after-tax earnings, rather than by weak operating economics, given the high gross margin. The trend suggests capital is compounding more slowly as earnings have declined, a dynamic that may indicate diminishing returns on recent capital deployment including acquisitions. Investors should distinguish between the structural capital intensity of the business and the cyclical drag from elevated pipeline spending.
Ample Liquidity With a Narrowing Cash Buffer
According to reported figures, UTHR's current ratio stands at 4.61 and quick ratio at 4.29 in 2026Q3, yet cash declined from $1.8B to $1.2B in a single quarter, which may indicate a thinner near-term buffer than headline ratios imply.
The very high current and quick ratios, with inventory days near 36, suggest the liquidity position is not dependent on inventory conversion, which is favorable under stress. However, the rapid drawdown in cash alongside rising acquisition outflows warrants investigation into whether capital deployment is outpacing operating cash generation. Under a severe stress scenario, the near-zero debt position provides meaningful flexibility, though the pace of cash consumption deserves continued scrutiny.
Misapplied Current Ratio Obscures Cash Trend
Based on reported figures, the current ratio of 4.61 is most commonly cited as evidence of financial strength, but it can mask the quarterly cash decline and the concentration of current assets in receivables and cash that do not reflect franchise durability.
For a recurring-therapy business with minimal inventory and no meaningful debt, the current ratio primarily reflects the level of retained cash and receivables rather than operating resilience, and it can overstate strength when liquidity is being deployed into acquisitions. A more informative alternative is free cash flow coverage of fixed commitments combined with a trend analysis of cash balances, which better captures whether the buffer is being maintained. Investors should treat the high current ratio as a necessary but insufficient indicator of financial health.